A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

350

Participants

Timeline

Start Date

September 20, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

August 31, 2026

Conditions
ObesityOverweight
Interventions
DRUG

LY3841136

Administered SC

DRUG

Tirzepatide

Administered SC

DRUG

Placebo

Administered SC

Trial Locations (52)

11776

North Suffolk Neurology, Port Jefferson Station

13057

Velocity Clinical Research, Syracuse, East Syracuse

14226

Dent Neurologic Institute, Amherst

14609

Rochester Clinical Research, LLC, Rochester

24541

Spectrum Medical, Inc., Danville

27405

Medication Management, Greensboro

28112

Monroe Biomedical Research, Monroe

28557

Lucas Research, Inc, Morehead City

28562

Lucas Research, Inc., New Bern

29607

Tribe Clinical Research, LLC, Greenville

32003

Northeast Research Institute (NERI), Fleming Island

32162

Charter Research - Lady Lake, The Villages

32803

Charter Research - Winter Park, Orlando

33012

Indago Research & Health Center, Inc, Hialeah

33165

New Horizon Research Center, Miami

34652

Suncoast Clinical Research, Inc., New Port Richey

37211

Quality Medical Research, Nashville

45212

CTI Clinical Research Center, Cincinnati

48034

Headlands Research - Detroit, Southfield

48098

Arcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy

50266

Iowa Diabetes and Endocrinology Research Center, West Des Moines

60077

NorthShore University Health System, Skokie

60640

Great Lakes Clinical Trials - Andersonville, Chicago

Great Lakes Clinical Trials - Ravenswood, Chicago

63303

StudyMetrix Research, City of Saint Peters

65807

Clinvest Headlands Llc, Springfield

66606

Cotton O'Neil Diabetes & Endocrinology, Topeka

75230

Velocity Clinical Research, Dallas, Dallas

75251

FutureSearch Trials of Dallas, Dallas

77079

PlanIt Research, PLLC, Houston

78229

Tekton Research - Fredericksburg Road, San Antonio

78240

Endeavor Clinical Trials, San Antonio

78596

Texas Valley Clinical Research, Weslaco

78745

IMA Clinical Research Austin, Austin

83406

Medical Research Partners, Ammon

85032

HOPE Research Institute, Phoenix

85225

The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler

85260

Headlands Research - Scottsdale, Scottsdale

85712

The Institute for Liver Health II dba Arizona Liver Health-Tucson, Tucson

89128

Las Vegas Medical Research, Las Vegas

90255

Velocity Clinical Research, Huntington Park, Huntington Park

90274

Peninsula Research Associates, Rolling Hills Estates

94598

Diablo Clinical Research, Inc., Walnut Creek

94904

NorCal Medical Research, Inc, Greenbrae

98801

Central Washington Health Services Association d/b/a Confluence Health, Wenatchee

06905

Stamford Therapeutics Consortium, Stamford

02492

Knownwell, Needham

02740

Lucida Clinical Trials, New Bedford

C1056ABI

Centro de Investigaciones Metabólicas (CINME), Buenos Aires

C1120AAC

Centro Médico Viamonte, Buenos Aires

C1405BUB

Consultorio de Investigación Clínica EMO SRL, Buenos Aires

C1425AGC

Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada, Buenos Aires

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT06603571 - A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes | Biotech Hunter | Biotech Hunter